Pharmaceuticals, Biotechnology and Life Sciences
First-of-its-kind therapeutic approach targets pathways intended to promote remyelination in people with relapsing-remitting multiple sclerosis Investigational platform technology is also…
—50% expansion and over $2 million investment in standalone analytical testing services (ATS); offers greater flexibility and agility to address…
THARROS is the first-ever prospective trial to investigate the potential of an inhaled triple therapy to reduce cardiopulmonary events, a…
Silence also announced positive topline 36-week data from ongoing phase 2 study of zerlasiran in patients with high lipoprotein(a) Company…
LYT-200 is being advanced in hematological malignancies such as acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), and locally…
ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report fourth…
Study met primary endpoint and demonstrated highly significant reductions in Lp(a) to week 36 Lipoprotein(a) reduction was consistent with phase…
PREVENAR 20® (20-valent Pneumococcal Conjugate Vaccine) offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect…
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers RAHWAY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known…
CHICAGO–(BUSINESS WIRE)–GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today the pricing of the previously announced…